Continue to Site

Drug Discovery and Development

Tazverik gaining momentum

By |

TAZVERIK EpizymeFDA has approved TAZVERIK from Epizyme for multiple indications.

The first-in-class EZH2 inhibitor is now indicated for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

The drug is also indicated for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. Finally, the agency has approved Tazverik’s use for patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

Filed Under: Oncology
Tagged With: , , , , ,
 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected]

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development